Patient-reported persistent symptoms after radiotherapy and association with quality of life for prostate cancer survivors

Authors

  • Sofia Spampinato a Danish Centre for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark
  • Tiziana Rancati b Data Science, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
  • Justyna Magdalena Waskiewicz c Department of Radiotherapy, Azienda Sanitaria dell’Alto Adige, Bolzano, Italy
  • Barbara Avuzzi d Department of Radiation Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
  • Elisabetta Garibaldi e Department of Radiotherapy, Ospedale Regionale Parini-AUSL Valle d’Aosta, Aosta, Italy
  • Adriana Faiella f Department of Radiotherapy, IRCCS Istituto Tumori ‘Regina Elena’, Rome, Italy
  • Elisa Villa g Department of Radiotherapy, Humanitas Gavazzeni, Bergamo, Italy
  • Alessandro Magli h Department of Radiotherapy, Azienda Ospedaliero Universitaria S. Maria della Misericordia, Udine, Italy
  • Domenico Cante i Department of Radiotherapy, ASL TO4 Ospedale di Ivrea, Ivrea, Italy
  • Giuseppe Girelli j Department of Radiotherapy, Ospedale degli Infermi, Biella, Italy
  • Marco Gatti k Department of Radiotherapy, Istituto di Candiolo – Fondazione del Piemonte per l‘Oncologia IRCCS, Candiolo, Italy
  • Barbara Noris Chiorda d Department of Radiation Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
  • Luciana Rago l Department of Radiotherapy, IRCCS CROB, Rionero in Vulture, Italy
  • Paolo Ferrari m Department of Health Physics, Provincial Hospital of Bolzano (SABES-ASDAA), Bolzano-Bozen, Italy; Lehrkrankenhaus der Paracelsus Medizinischen Privatuniversität
  • Cristina Piva i Department of Radiotherapy, ASL TO4 Ospedale di Ivrea, Ivrea, Italy
  • Maddalena Pavarini n Department of Medical Physics, IRCCS San Raffaele Scientific Institute, Milan, Italy
  • Riccardo Valdagni d Department of Radiation Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
  • Vittorio Vavassori g Department of Radiotherapy, Humanitas Gavazzeni, Bergamo, Italy
  • Fernando Munoz e Department of Radiotherapy, Ospedale Regionale Parini-AUSL Valle d’Aosta, Aosta, Italy
  • Giuseppe Sanguineti f Department of Radiotherapy, IRCCS Istituto Tumori ‘Regina Elena’, Rome, Italy
  • Nadia Di Muzio o Department of Radiotherapy, San Raffaele Scientific Institute and Università Vita Salute San Raffaele, Milan, Italy
  • Kathrin Kirchheiner p Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
  • Claudio Fiorino n Department of Medical Physics, IRCCS San Raffaele Scientific Institute, Milan, Italy
  • Cesare Cozzarini q Department of Radiotherapy, IRCCS San Raffaele Scientific Institute, Milan, Italy

DOI:

https://doi.org/10.1080/0284186X.2023.2259597

Keywords:

clinical study, prostate cancer, quality of life, radiotherapy, side effects

Abstract

Purpose

To evaluate the persistence of symptoms after radiotherapy (RT) for localised prostate cancer (PCa) and the association with quality of life (QOL).

Materials and methods

Prospective patient-reported outcome (PRO) from a multi-institutional study on PCa treated with radical RT (2010–2014) was analysed. Data was collected at baseline (BL) and follow-ups (FUPs) up to 5 years. Patients with BL and ≥3 late FUPs (≥6 months) were analysed. PRO was scored by means of the IPSS and ICIQ-SF (urinary), LENT-SOMA (gastrointestinal [GI]), and EORTC-C30 (pain, insomnia, fatigue, and QOL) questionnaires. Symptoms were defined ‘persistent’ if the median score over FUPs was ≥3 (urinary) or ≥2 (GI, pain, insomnia, and fatigue), and worse than BL. Different thresholds were chosen to have enough events for each symptom. QOL was linearly transformed on a continuous scale (0–100). Linear-mixed models were used to identify significant differences between groups with and without persistent symptoms including age, smoking status, previous abdominal surgery, and diabetes as confounders. Mean QOL differences between groups were evaluated longitudinally over FUPs.

Results

The analysis included 293 patients. Persistent urinary symptoms ranged from 2% (straining) to 12% (weak stream, and nocturia). Gastrointestinal symptoms ranged from 7% (rectal pain, and incontinence) to 30% (urgency). Proportions of pain, insomnia, and fatigue were 6, 13, and 18%. Significant QOL differences of small-to-medium clinical relevance were found for urinary incontinence, frequency, urgency, and nocturia. Among GI symptoms, rectal pain and incontinence showed small-to-medium differences. Fatigue was associated with the largest differences.

Conclusions

The analysis showed that symptoms after RT for PCa occur with different persistence and their association with QOL varies in magnitude. A number of persistent urinary and GI symptoms showed differences in a comparable range. Urinary incontinence and frequency, rectal pain, and faecal incontinence more often had significant associations. Fatigue was also prevalent and associated with largely deteriorated QOL.

Downloads

Download data is not yet available.

Downloads

Additional Files

Published

2023-11-02

How to Cite

Spampinato, S., Rancati, T., Magdalena Waskiewicz, J., Avuzzi, B., Garibaldi, E., Faiella, A., … Cozzarini, C. (2023). Patient-reported persistent symptoms after radiotherapy and association with quality of life for prostate cancer survivors. Acta Oncologica, 62(11), 1440–1450. https://doi.org/10.1080/0284186X.2023.2259597